These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24887353)

  • 41. Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.
    Stadler ZK; Kauff ND
    J Clin Oncol; 2010 Jan; 28(2):189-91. PubMed ID: 19996025
    [No Abstract]   [Full Text] [Related]  

  • 42. Oophorectomy in carriers of BRCA mutations.
    Whitfield GA
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353513
    [No Abstract]   [Full Text] [Related]  

  • 43. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
    McEwen AR; McConnell DT; Kenwright DN; Gaskell DJ; Cherry A; Kidd AM
    Gynecol Oncol; 2004 Mar; 92(3):992-4. PubMed ID: 14984974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
    Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Risk-reducing surgery in women at hereditary risk of gynaecological cancer].
    Zikán M
    Ceska Gynekol; 2011 Jun; 76(3):216-21. PubMed ID: 21838153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic approaches for women predisposed to breast cancer.
    Nathanson KL; Domchek SM
    Annu Rev Med; 2011; 62():295-306. PubMed ID: 21034216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
    J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
    Powell CB
    Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
    [No Abstract]   [Full Text] [Related]  

  • 51. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
    Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
    [No Abstract]   [Full Text] [Related]  

  • 53. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
    Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
    Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
    Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
    Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
    Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
    Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
    Brekelmans CT; Seynaeve C
    Lancet Oncol; 2006 Mar; 7(3):191-3. PubMed ID: 16510328
    [No Abstract]   [Full Text] [Related]  

  • 57. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oophorectomy in carriers of BRCA mutations.
    Zhuang SH; Leonard GD; Swain SM
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12324566
    [No Abstract]   [Full Text] [Related]  

  • 59. Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
    Saule C; Mouret-Fourme E; Briaux A; Becette V; Rouzier R; Houdayer C; Stoppa-Lyonnet D
    J Natl Cancer Inst; 2018 Feb; 110(2):. PubMed ID: 28954295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.